[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma director and CEO Neil Kumar reported transactions on 08/16/2025 showing vesting and tax-withholding activity tied to Restricted Stock Units (RSUs). A total of 64,697 RSU shares vested (reported as acquisition), and 32,855 shares were withheld to satisfy tax obligations at an indicated price of $51.32 per share. After these transactions the reporting person directly beneficially owned 282,101 shares and indirectly beneficially owned 4,718,447 and 915,686 shares through two trusts, of which he is co-trustee. Multiple tranches of RSUs continue to vest quarterly with no expiration.

Positive

• Vesting of 64,697 RSU shares increases the executive's aligned equity stake
• Large indirect holdings (4,718,447 and 915,686 shares) demonstrate substantial long-term economic exposure
• RSUs vest quarterly with no expiration, indicating ongoing alignment with company performance

Negative

• 32,855 shares withheld to satisfy taxes at $51.32 reduced direct beneficial ownership
• Potential dilution from vested RSUs as they convert into common stock

Insights

Financial Analyst

TL;DR: Insider vested RSUs increased share exposure while a routine tax-withholding sale reduced direct holdings.

The filing documents customary executive compensation mechanics: vesting of 64,697 RSU shares increases potential share issuance and long-term alignment, while withholding of 32,855 shares at $51.32 is a non-dispositive tax-related disposition that lowers direct share count. The large indirect holdings via two trusts (totaling 5,634,134 shares) indicate substantial overall economic exposure despite the net change in direct shares. These transactions are typical for executive equity compensation and not an indicator of a material change in control or strategy.

Corporate Governance Expert

TL;DR: Transactions reflect standard vesting and tax withholding; disclosure and trust structures are properly noted.

Form 4 shows clear disclosure of direct and indirect ownership and the nature of indirect holdings through revocable and irrevocable trusts, with the required disclaimer of beneficial ownership limited to pecuniary interest. The continuing quarterly vesting schedule and lack of expiration for RSUs are governance-relevant for dilution modeling. No departures, option exercises for cash proceeds, or other atypical governance events are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/16/2025		M		64,697	A	(1)	282,101	D
Common Stock	08/16/2025		F		32,855(2)	D	$51.32	249,246	D
Common Stock								4,718,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								915,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/16/2025		M			33,544	(4)	(4)	Common Stock	33,544	$0	201,264	D
Restricted Stock Units	(1)	08/16/2025		M			19,599	(5)	(5)	Common Stock	19,599	$0	195,993	D
Restricted Stock Units	(1)	08/16/2025		M			11,554	(6)	(6)	Common Stock	11,554	$0	161,753	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

5. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

6. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

	/s/ Laura Woodhead, Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Neil Kumar report on Form 4 for BBIO?

The filing reports vesting of 64,697 RSU shares on 08/16/2025 and a withholding of 32,855 shares to cover taxes at $51.32 per share.

How many shares does the reporting person directly and indirectly own after the transactions?

After the reported transactions the reporting person directly beneficially owned 282,101 shares and indirectly owned 4,718,447 and 915,686 shares through two trusts.

Why were 32,855 shares disposed of according to the filing?

The filing states those shares were withheld to satisfy the Reporting Person's tax obligation in connection with RSU vesting.

Do the RSUs reported have an expiration date?

No, the filing specifies the RSUs have no expiration date and vest quarterly following initial partial vesting dates.

What trusts hold indirect shares for the reporting person?

Indirect holdings are held by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where the reporting person is a co-trustee.

Does the Form 4 indicate any change in the reporting person's role at BridgeBio?

No; the filing lists the reporting person as Director and Chief Executive Officer and does not disclose any role change.